LICENSE AGREEMENT No. 206-01.LICLicense Agreement • August 12th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances) • Arizona
THIS AGREEMENT (the “Agreement”), made this 2nd day of August, 1999 (the “EFFECTIVE DATE”), is by and between the ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting on behalf of and for ARIZONA STATE UNIVERSITY, of Tempe, Arizona (“ASU”) and OXiGENE Europe AB, a corporation organized under the laws of Sweden having its principal place of business located at Blasieholmsgatan 2c, S-111 48 Stockholm, Sweden (“LICENSEE”), a subsidiary of OXiGENE Inc., a Delaware corporation having its principal place of business located at One Copley Place, Suite 602, Boston, MA 02116.
Agreement to Amend Research and License AgreementResearch and License Agreement • August 12th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances)
This Agreement, dated as of April 23, 2002, is by and between OXiGENE, Inc. 321 Arsenal Street, Watertown, Massachusetts 02472 (“OXiGENE”) and Baylor University, Waco, Texas 76798 (the “University”). OXiGENE and the University may be referred to collectively as the “Parties” or individually as a “Party.”
OXIGENE, INC. RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • August 12th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances) • Texas
This Agreement, dated as of June 1, 1999 (the “Effective Date”), between OXiGENE, Inc., One Copley Place, Suite 602, Boston, MA 02116 (“OXiGENE”) and Baylor University, Waco, Texas 76798 (the “University”).
ContractOxigene Inc • August 12th, 2003 • Biological products, (no disgnostic substances)
With the understanding that all material aspects of both the June 1, 1999, Research and License Agreement and the April 23, 2002, Agreement to Amend Research and License Agreement remain in full force and effect, the parties hereby agree to amend and restate Appendix C, which is attached hereto, to include all elected Inventions included therein, pursuant to Section 4.2 of the June 1, 1999, Research and License Agreement.
License AgreementLicense Agreement • August 12th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances)
This License Agreement, entered into as of November 16, 2001, (“Effective Date”) is made by and between Active Biotech AB (publ), a Swedish company having registration number 556223-9227 and having its registered office at Scheelevägen 22, SE-220 07 Lund, Sweden (“Active”), and Oxigene Inc., an American company having offices at 321 Arsenal Street, Watertown, MA 02472, USA (“Oxigene”).
LICENSE AGREEMENTLicense Agreement • August 12th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances)
This License Agreement, entered into as of April 23, 2002, (“Effective Date”) is made by and between Active Biotech AB (publ), a Swedish company having registration number 556223-9227 and having its registered office at Scheelevägen 22, SE-220 07 Lund, Sweden (“Active”), and OXiGENE Inc., a company duly organized and existing under the laws of the state of Delaware in the United States and having offices at 321 Arsenal Street, Watertown, Massachusetts, U.S.A. 02472, for and on behalf of itself and its Affiliates (“OXiGENE”).
